Second- and third-generation beta-blocking drugs in chronic heart failure

Michael R. Bristow; William T. Abraham; Tsutomu Yoshikawa; Michel White; Brack G. Hattler; Thomas S. Crisman; Brian D. Lowes; A. D. Robertson; Patti Larrabee; Edward M. Gilbert

doi:10.1023/A:1007748131847

Second- and third-generation beta-blocking drugs in chronic heart failure

Michael R. Bristow, William T. Abraham, Tsutomu Yoshikawa, Michel White, Brack G. Hattler, Thomas S. Crisman, Brian D. Lowes, A. D. Robertson, Patti Larrabee, Edward M. Gilbert

Research output: Contribution to journal › Article › peer-review

33 Scopus citations

Abstract

The left-ventricular (LV) functional, hemodynamic, and antiadrenergic effects of metoprolol, bucindolol, and carvedilol have been compared in three concurrent placebo-controlled clinical trials in patients with symptomatic idiopathic dilated cardiomyopathy. All three drugs were well tolerated, all produced at least moderate degrees of β-blockade as assessed by reduction in exercise heart rate, and all increased the left-ventricular ejection fraction. Compared with the β₁-selective, second-generation compound metoprolol, the third-generation compounds bucindolol and carvedilol lowered indices of adrenergic activity and tended to improve LV function to a greater extent. In patients with chronic heart failure there may be important therapeutic response differences between second- and third-generation beta-blocking agents.

Original language	English (US)
Pages (from-to)	291-296
Number of pages	6
Journal	Cardiovascular Drugs and Therapy
Volume	11
Issue number	SUPPL. 1
DOIs	https://doi.org/10.1023/A:1007748131847
State	Published - 1997
Externally published	Yes

Keywords

Antiadrenergic activity
Beta-blocking drugs
Chronic heart failure
Exercise response
Idiopathic dilated cardiomyopathy
Ischemic cardiomyopathy
Left ventricular function

ASJC Scopus subject areas

Pharmacology
Cardiology and Cardiovascular Medicine
Pharmacology (medical)

Access to Document

10.1023/A:1007748131847

Fingerprint Dive into the research topics of 'Second- and third-generation beta-blocking drugs in chronic heart failure'. Together they form a unique fingerprint.

Cite this

Second- and third-generation beta-blocking drugs in chronic heart failure. / Bristow, Michael R.; Abraham, William T.; Yoshikawa, Tsutomu; White, Michel; Hattler, Brack G.; Crisman, Thomas S.; Lowes, Brian D.; Robertson, A. D.; Larrabee, Patti; Gilbert, Edward M.

In: Cardiovascular Drugs and Therapy, Vol. 11, No. SUPPL. 1, 1997, p. 291-296.

Research output: Contribution to journal › Article › peer-review

@article{2025b5e968a042df88a36cda4933852d,

title = "Second- and third-generation beta-blocking drugs in chronic heart failure",

abstract = "The left-ventricular (LV) functional, hemodynamic, and antiadrenergic effects of metoprolol, bucindolol, and carvedilol have been compared in three concurrent placebo-controlled clinical trials in patients with symptomatic idiopathic dilated cardiomyopathy. All three drugs were well tolerated, all produced at least moderate degrees of β-blockade as assessed by reduction in exercise heart rate, and all increased the left-ventricular ejection fraction. Compared with the β1-selective, second-generation compound metoprolol, the third-generation compounds bucindolol and carvedilol lowered indices of adrenergic activity and tended to improve LV function to a greater extent. In patients with chronic heart failure there may be important therapeutic response differences between second- and third-generation beta-blocking agents.",

keywords = "Antiadrenergic activity, Beta-blocking drugs, Chronic heart failure, Exercise response, Idiopathic dilated cardiomyopathy, Ischemic cardiomyopathy, Left ventricular function",

author = "Bristow, {Michael R.} and Abraham, {William T.} and Tsutomu Yoshikawa and Michel White and Hattler, {Brack G.} and Crisman, {Thomas S.} and Lowes, {Brian D.} and Robertson, {A. D.} and Patti Larrabee and Gilbert, {Edward M.}",

year = "1997",

doi = "10.1023/A:1007748131847",

language = "English (US)",

volume = "11",

pages = "291--296",

journal = "Cardiovascular Drugs and Therapy",

issn = "0920-3206",

publisher = "Kluwer Academic Publishers",

number = "SUPPL. 1",

}

TY - JOUR

T1 - Second- and third-generation beta-blocking drugs in chronic heart failure

AU - Bristow, Michael R.

AU - Abraham, William T.

AU - Yoshikawa, Tsutomu

AU - White, Michel

AU - Hattler, Brack G.

AU - Crisman, Thomas S.

AU - Lowes, Brian D.

AU - Robertson, A. D.

AU - Larrabee, Patti

AU - Gilbert, Edward M.

PY - 1997

Y1 - 1997

N2 - The left-ventricular (LV) functional, hemodynamic, and antiadrenergic effects of metoprolol, bucindolol, and carvedilol have been compared in three concurrent placebo-controlled clinical trials in patients with symptomatic idiopathic dilated cardiomyopathy. All three drugs were well tolerated, all produced at least moderate degrees of β-blockade as assessed by reduction in exercise heart rate, and all increased the left-ventricular ejection fraction. Compared with the β1-selective, second-generation compound metoprolol, the third-generation compounds bucindolol and carvedilol lowered indices of adrenergic activity and tended to improve LV function to a greater extent. In patients with chronic heart failure there may be important therapeutic response differences between second- and third-generation beta-blocking agents.

AB - The left-ventricular (LV) functional, hemodynamic, and antiadrenergic effects of metoprolol, bucindolol, and carvedilol have been compared in three concurrent placebo-controlled clinical trials in patients with symptomatic idiopathic dilated cardiomyopathy. All three drugs were well tolerated, all produced at least moderate degrees of β-blockade as assessed by reduction in exercise heart rate, and all increased the left-ventricular ejection fraction. Compared with the β1-selective, second-generation compound metoprolol, the third-generation compounds bucindolol and carvedilol lowered indices of adrenergic activity and tended to improve LV function to a greater extent. In patients with chronic heart failure there may be important therapeutic response differences between second- and third-generation beta-blocking agents.

KW - Antiadrenergic activity

KW - Beta-blocking drugs

KW - Chronic heart failure

KW - Exercise response

KW - Idiopathic dilated cardiomyopathy

KW - Ischemic cardiomyopathy

KW - Left ventricular function

UR - http://www.scopus.com/inward/record.url?scp=8244249474&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=8244249474&partnerID=8YFLogxK

U2 - 10.1023/A:1007748131847

DO - 10.1023/A:1007748131847

M3 - Article

C2 - 9211023

AN - SCOPUS:8244249474

VL - 11

SP - 291

EP - 296

JO - Cardiovascular Drugs and Therapy

JF - Cardiovascular Drugs and Therapy

SN - 0920-3206

IS - SUPPL. 1

ER -

Second- and third-generation beta-blocking drugs in chronic heart failure

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Cite this